All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-11-15T12:39:08.000Z

FDA approves zanubrutinib for the treatment of adult patients with R/R MCL

Nov 15, 2019
Share:

Bookmark this article

On the 14th November 2019, the U.S. Food and Drug Administration (FDA) approved zanubrutinib (BGB-3111) for the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).1 Earlier this year, the drug received  Breakthrough Therapy designation by the FDA and a Priority Review designation.

Zanubrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK), a protein involved in pathways regulating B-cell proliferation, chemotaxis, and adhesion. The approval was granted based on the positive data from the multicentre phase II trial of zanubrutinib in patients with R/R MCL (NCT03206970), showing overall response rate (ORR) of 84% (95% CI: 74%, 91%), including 59% complete response (CR).2 The median duration of response (DOR) was 19.5 months and the median follow-up time was 18.4 months. The supporting phase I/II single-arm trial (NCT02343120) also showed 84% ORR, including 22% CR and 62% partial response with a median DOR of 18.5 months.1,2

The most common adverse events were decreased neutrophil and platelet count, infections of the upper respiratory tract, cough, decreased white blood cell count, decreased hemoglobulin, rash, and diarrhea.1

Clinical trials of zanubrutinib as a single agent are also ongoing in patients with untreated MCL and Waldenström macroglobulinemia. Other studies investigate the combination of zanubrutinib and obinutuzumab for treatment-naive and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma, and R/R follicular lymphoma.

  1. FDA. FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage. News release. November 14 2019.  https://www.fda.gov/news-events/press-announcements/fda-approves-therapy-treat-patients-relapsed-and-refractory-mantle-cell-lymphoma-supported-clinical. [Accessed: November 15 2019]
  2. BeiGene. U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy.Press release. November 14 2019. https://www.globenewswire.com/news-release/2019/11/14/1947617/0/en/U-S-FDA-Grants-BeiGene-s-BRUKINSA-zanubrutinib-Accelerated-Approval-to-Treat-Adult-Patients-with-Mantle-Cell-Lymphoma-Who-Received-at-Least-One-Prior-Therapy.html  [Accessed: November 15 2019]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox